Clinical trials
CAR-T clinical trials
Below are recruiting car-t clinical trials, each written for real people, not researchers. We’re tracking 459 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06983964Recruiting
CAR-T cell therapy for autoimmune diseases that haven't improved
This trial tests a personalized cell therapy (CAR-T) that targets a protein called CD19 on immune cells. It's for people with certain autoimmune diseases like lupus or scleroderma that are still active despite standard treatments. The goal is to see if this therapy can help control the disease when other options haven't worked.
Beijing, Beijing MunicipalityAges 18–65 - NCT06988059RecruitingEarly Phase 1
Car T-cell therapy for plasma cell leukemia
This trial tests a new Car T-cell treatment called CT0596 for patients with plasma cell leukemia, a rare and aggressive blood cancer. It aims to see if this therapy can help control the disease in patients who have already tried other treatments.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07008885RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed/refractory B-ALL
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
Beijing, Biotherapeutic Department of Chinese PLA General HospitalAges 18–70 - NCT07009002RecruitingPhase 1/Phase 2
Modified CAR-T cell therapy for relapsed B-cell lymphoma
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT07031713RecruitingPhase 1
Testing CT1192 cells for lupus that hasn't responded to treatment
This trial tests a new treatment called CT1192, which uses your own immune cells (T-cells) that are modified to target and calm overactive immune cells causing lupus. It is designed for people with moderate to severe lupus that hasn't improved with standard therapies like steroids, immunosuppressants, or biologics.
Wuhan, HubeiAges 18–60 - NCT07036250RecruitingPhase 1/Phase 2
Study of U32 for acute myeloid leukemia
This trial tests a new treatment called U32 for people with acute myeloid leukemia (AML) that has come back or not responded to prior therapy. It aims to see if targeting certain proteins on leukemia cells can help control the disease.
SuzhouAges 2–65 - NCT07051850Recruiting
Quality of life study for relapsed myeloma immunotherapy
This study compares quality of life and treatment results in people with relapsed or refractory multiple myeloma who receive either newer or standard immunotherapy. It aims to understand how these treatments affect daily living and outcomes.
Seocho, SeoulAges 19 years+ - NCT07052565Recruiting
CAR-T cell therapy for autoimmune diseases
This trial uses your own engineered immune cells (CAR-T cells) to treat severe autoimmune diseases like rheumatoid arthritis, lupus, Sjögren's syndrome, or systemic sclerosis that haven't improved with standard medicines. The goal is to see if this treatment can calm the immune system and reduce disease activity.
HefeiAges 18 years+ - NCT07059169Recruiting
CAR-T cell therapy for severe autoimmune diseases
This trial tests a one-time CAR-T cell therapy for people with severe autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, dermatomyositis, or ANCA vasculitis. It aims to reset the immune system and reduce disease activity for those who haven't responded well to standard treatments.
Wuhan, HubeiAges 18 years+ - NCT07072247RecruitingPhase 1
RN1201 injection for hard-to-treat antibody-mediated blood disorders
This trial tests a new injection called RN1201 for people with antibody-mediated diseases, specifically two types of blood disorders: platelet transfusion refractoriness (PTR) and immune thrombocytopenia (ITP) that haven't responded to standard treatments. The goal is to see if RN1201 can help control these conditions.
Suzhou, JiangsuAges 16–65 - NCT07085676RecruitingPhase 1
CAR-T cell therapy for autoimmune diseases that resist treatment
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
JerusalemAges 18–80 - NCT07106671RecruitingPhase 2
Siltuximab for side effects after CAR-T in multiple myeloma
This trial tests if the drug Siltuximab can help control side effects (CRS and ICANS) that sometimes happen after CAR-T treatment for multiple myeloma. It may help patients who develop these symptoms.
TianjinAges 18 years+ - NCT07108868RecruitingPhase 1
Study of MB-CART2219.1 for blood cancers
This trial tests a new CAR T-cell therapy called MB-CART2219.1 in people with certain types of blood cancer (like lymphoma or leukemia) that have come back or not responded to other treatments. CAR T-cells are your own immune cells that are modified to better find and kill cancer cells.
Tübingen, Baden-WurttembergAges 12–75 - NCT07109323RecruitingPhase 1/Phase 2
Stem cell transplant plus CAR-T for aggressive myeloma
This trial tests combining a stem cell transplant with a special immune cell therapy (BCMA CAR-T) to treat very aggressive multiple myeloma. The goal is to see if this powerful one-two punch can help people whose myeloma is hard to control.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07135466RecruitingPhase 1/Phase 2
Anti-CD22 CAR T-cell therapy for B-cell blood cancers
This trial tests a new treatment using your own immune cells (T-cells) that are modified to find and attack cancer cells with a marker called CD22. It is for people with B-cell blood cancers that have come back or not responded to at least two prior treatments, including a type of immunotherapy called CAR T-cell therapy.
Ramat Gan, GAges 1–80 - NCT07169500RecruitingPhase 1/Phase 2
CAR-T with or without stem cell transplant for young women with myeloma
This trial tests a new immune cell therapy (BCMA-CART) alone or combined with a stem cell transplant for women aged 18-55 with multiple myeloma. It aims to see if this treatment is safe and effective.
Tianjin, Tianjin MunicipalityAges 18–50 - NCT07173166Recruiting
Managing side effects after CAR-T treatment
This study tests if non-drug approaches like lifestyle changes or supportive care can reduce nerve-related side effects in people with blood cancers who are receiving CAR-T therapy. It aims to help patients feel better during treatment.
Valencia, ValenciaAges 18–80 - NCT07173322Recruiting
How CAR-T cell therapy affects fertility: a patient survey
This study is a survey to understand how CAR-T cell therapy might affect fertility. If you have had CAR-T cell treatment, your answers can help doctors learn more about its long-term effects.
Rye, New YorkAges 18 years+ - NCT07180927RecruitingPhase 1/Phase 2
DLL3 car-t therapy for recurrent brain tumors
This trial tests a new immune therapy called DLL3 CAR-T cells for people with brain tumors that have come back or not responded to treatment. It aims to see if these specially designed cells can attack the tumor safely.
Shenzhen, GuangdongAges 2–70 - NCT07186192RecruitingPhase 3
Digital health app for CAR-T therapy self-management
This study tests a digital health app to help you manage symptoms and stay connected with your care team while receiving CAR-T therapy as an outpatient. It's designed for people with blood cancers who have a caregiver living with them.
Duarte, CaliforniaAges 18 years+ - NCT07198867RecruitingPhase 1
A-CAR028 for relapsed or refractory AML
This trial tests a new cell therapy called A-CAR028 for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses your own immune cells to fight the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT07200102RecruitingPhase 1
Selinexor after CAR-T for high-risk multiple myeloma
This trial tests if the drug selinexor can help prevent multiple myeloma from coming back after CAR-T cell therapy. It is for people with high-risk or persistent myeloma who have already received a specific CAR-T treatment called Carvykti.
St Louis, MissouriAges 18 years+ - NCT07212335RecruitingEarly Phase 1
Stem cells for low blood counts after CAR-T
This trial tests if umbilical cord stem cells can help restore low blood counts in people with leukemia, lymphoma, or myeloma who still have low blood cell levels three weeks after CAR-T therapy. It aims to improve recovery and reduce infection or bleeding risks.
TianjinAges 18 years+ - NCT07223021RecruitingPhase 3
Fludarabine dosing study for B-cell ALL
This study tests a different dose of the chemotherapy drug fludarabine before CAR T-cell therapy (tisagenlecleucel) for children and young adults with B-cell acute lymphoblastic leukemia. The goal is to see if the new dose works better at helping the body accept the CAR T cells while keeping side effects manageable.
New York, New YorkAges 1 year+
Hear when a new CAR-T trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for car-t?
- Yes. Clin2 currently lists 459 recruiting car-t studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a car-t trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a car-t trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.